Press Releases

  • Takeda and MSD mutually agree to end co-promotion agreement for Daxas


    Zurich, Switzerland, December 22, 2011 -- Takeda Pharmaceuticals International GmbH today announced that it has reached a mutual agreement with Merck & Co., Inc. (based in Whitehouse Station, New Jersey and known as MSD outside the USA and Canada) to terminate their co-promotion agreement for Daxas® (roflumilast) in certain European countries and Canada as of December 31, 2011. MSD will return the rights to Daxas® to Takeda in all countries covered by the agreement.

  • Steovess® accepted for national approvals in European Union


    Zurich, Switzerland, December 20, 2011 - Takeda Pharmaceuticals International GmbH (“Takeda”) today announced that the European decentralised procedure (DCP) was positively concluded for Steovess® (formerly known as EX101), a once-a-week 70mg buffered effervescent alendronate for the treatment of post-menopausal osteoporosis.

  • Takeda Appoints Jostein Davidsen Head of Emerging Markets


    Nycomed, a Takeda Company, today announced that Jostein Davidsen has been appointed Head of Emerging Markets in addition to his current role as Area Head of Russia/CIS. He will report to Frank Morich, EVP, International Operations (Americas/Europe), Takeda Pharmaceuticals International, and CEO of Nycomed. The appointment is effective immediately.

  • Takeda completes acquisition and names new CEO of Nycomed


    OSAKA, Japan, September 30, 2011 – Takeda Pharmaceutical Company Limited (“Takeda”, TSE: 4502) announced it has completed its acquisition of Nycomed A/S (“Nycomed”) for 9.6 billion Euro on a cash-free, debt-free basis and made Nycomed a wholly owned subsidiary of Takeda effective the same day. Dr. Frank Morich has been named CEO of Nycomed in addition to his current role as Executive Vice President (EVP), International Operations (Americas/Europe), Takeda Pharmaceuticals International, Inc., a wholly owned subsidiary of Takeda America Holdings, Inc.

  • Nycomed and Almirall announce a licensing agreement for ebastine 


    Nycomed and Almirall today announced that they have signed a licensing and supply agreement for Almirall’s R&D antihistamine ebastina, under the trademark Kestine®, indicated for allergic rhinitis and chronic idiopathic urticaria, in China and other key emerging markets.

  • New data analysis supports the use of Daxas


    Nycomed today announced new findings to show that Daxas® (roflumilast) helps to prevent exacerbations in COPD patients of the ‘frequent exacerbator’ phenotype. The data, presented at the 2011 European Respiratory Society (ERS) Annual Congress in Amsterdam, 24 – 28 September, have important implications for the management of COPD in this patient population, who are at increased risk of disease progression compared with those who have no or infrequent exacerbations. Frequent exacerbations are of concern to a significant group of COPD patients, despite access to available therapy.  They are distressing for patients and lead to poorer health status and faster disease progression, imposing a substantial burden on patients.  Exacerbations also significantly impact the functional ability of COPD patients – patients with frequent exacerbations reduce the time they spend outdoors at a faster rate compared with those with infrequent exacerbations and are more likely to become housebound.

  • Nycomed and Norgine sign a Licence Agreement for MOVIPREP in Russia/CIS


    Nycomed and Norgine, a European specialty pharmaceutical company,  today announced that they have entered into a licensing agreement that gives Nycomed the exclusive rights to commercialise MOVIPREP, the worlds leading bowel cleansing brand, in Russia, Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Mongolia, Tajikistan, Turkmenistan, Ukraine, and Uzbekistan.

  • Nycomed reports double-digit growth across emerging markets in second quarter 2011


    Nycomed today announced results for the second quarter of 2011, achieving double digit growth across emerging markets. Good progress was made in Key Products, particularly in the respiratory area. Following U.S. approval of Daliresp™ for the treatment of COPD earlier this year, Nycomed's partner Forest Laboratories introduced the product to the market and is preparing a full launch in the third quarter. In May, Nycomed agreed to be acquired by Takeda, subject to antitrust clearance, creating a truly global pharmaceutical business equipped to meet the needs of patients, doctors and healthcare providers.

  • Nycomed and Orion Corporation to collaborate on Easyhaler® for asthma and COPD


    Nycomed announced today that it has entered into a collaboration agreement with Orion Corporation (Nasdaq OMX Helsinki: ORNAV and ORNBV) for the co-marketing of Easyhaler® combination products for the treatment of asthma and COPD in the major European countries and an exclusive license and distribution arrangement for the Middle East and North Africa region (MENA). Both companies will commercialise Easyhaler combination products under their own brands accompanied by the Easyhaler umbrella brand.

  • Nycomed’s Instanyl® (fentanyl) single-dose nasal spray receives European approval


    Nycomed today announced that the European Commission has granted marketing authorisation for its Instanyl® single-dose nasal spray. The single-dose nasal spray marks another innovation by Nycomed in the management of breakthrough pain in cancer patients and will be available in European countries from September 2011.

  • Nycomed to market Roche’s osteoporosis treatment Bonviva in key Asia-Pacific markets


    Nycomed today announced that it has completed the transfer of marketing authorisation approvals in a number of key Asia-Pacific markets for osteoporosis treatment Bonviva (Ibandronate). The licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) marks a further strengthening of Nycomed’s bone health franchise in the region.

  • FDA accepts filing of New Drug Application for Nycomed’s ciclesonide HFA nasal aerosol


    Nycomed’s licensing partner Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) submitted for ciclesonide nasal aerosol in a hydrofluoroalkane (HFA) formulation.  The proposed dosing for ciclesonide HFA nasal aerosol is 74 mcg once-daily (37 mcg per spray; one-spray per nostril) and the proposed indication is for the treatment of symptoms of Seasonal Allergic Rhinitis (SAR) and Perennial Allergic Rhinitis (PAR), in adults and adolescents age 12 and older.  Nycomed granted Sunovion exclusive development, marketing and commercialization rights for ciclesonide in the United States.

  • Nycomed continues to outperform in emerging markets in first quarter 2011


    Nycomed today announced results for the first quarter of 2011, demonstrating continued outperformance in the key emerging economies which are driving growth in the global pharmaceuticals industry. There was good growth in Nycomed’s Key Products portfolio (excluding Pantoprazole, which is now off patent worldwide), led by respiratory, OTC and Regional and Local Rx products.

  • Takeda to Acquire Nycomed


    Takeda Pharmaceutical Company Limited (“Takeda”, TSE: 4502) and Nycomed A/S (“Nycomed”) jointly announced today that Takeda has reached an agreement with the shareholders of Nycomed in which Takeda will acquire the Zurich-headquartered company for 9.6 billion Euro on a cash-free, debt-free basis. The boards of directors of each company unanimously approved the transaction which is expected to be completed within 90 to 120 days, making it a wholly owned subsidiary of Takeda, subject to antitrust clearance. The purchase would exclude Nycomed’s U.S. dermatology business.

  • Commercialization agreement for roflumilast in Spain


    Nycomed and Almirall today announced that they have entered into a co-branding agreement for the commercialization of roflumilast in Spain. Roflumilast is a once-daily tablet for patients with chronic obstructive pulmonary disease (COPD).  It is an orally administered phosphodiesterase 4 (PDE4) enzyme inhibitor, and the first oral anti-inflammatory treatment for COPD.

  • Nycomed acquires distribution rights to product portfolio in Turkey


    Nycomed announced today that it has entered into several agreements with various pharmaceutical companies, including Almirall S.A., Anika Therapeutics, Inc., Bionorica AG, CSL Behring and Helsinn Healthcare SA. With this transaction, Nycomed replaces the specialty pharmaceutical company Biomeks İlaç (Biomeks) as the marketing authorization holder and distributor for the majority of Biomeks’ product portfolio in Turkey. The portfolio includes more than ten pharmaceutical products, which generated €10 million in net sales in 2010.

  • Nycomed announces REACT study to evaluate impact of Daxas® (roflumilast)


    Nycomed today announced plans for an international phase III/IV study investigating the effect of Daxas® (500μg tablets, once daily) versus placebo on exacerbation rates in COPD patients who are concomitantly treated with fixed combination long-acting-ß2-agonists (LABA) and inhaled corticosteroids (ICS), with or without a long-acting muscarinic antagonist (LAMA). Use of Daxas® with the individual components of fixed combination and triple therapy has already been shown to reduce exacerbations and improve lung function. ,  The REACT study is the first to investigate Daxas when used in patients concomitantly treated with fixed combination treatment or triple therapy.

  • Nycomed submits European MAA for teduglutide (Revestive®)


    Nycomed has announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency for teduglutide (Revestive®) as a once-daily subcutaneous treatment for Short Bowel Syndrome (SBS). Teduglutide is a novel, recombinant analogue of human glucagon-like peptide 2 (GLP-2), a protein involved in the rehabilitation of the intestinal lining. Revestive® has received orphan drug designation as SBS is a rare disease affecting less than 10,000 patients in Europe.

  • Nycomed well positioned in emerging markets


    Nycomed’s 2010 performance continued to show above industry average growth in emerging markets, as well as strong growth of Key Products (excluding pantoprazole), Regional and Local prescription (Rx) drugs. Net turnover was steady with a slight decrease by 1.8% to € 3,170.6 million in 2010 from € 3,228.0 million in 2009 (+0.4%, excluding one-time payment from Forest Laboratories in 2009). The decrease was primarily driven by declining sales of pantoprazole due to the loss of patent exclusivity in several markets, including Australia and Switzerland, and the full-year impact of the expiry of the pantoprazole patent in other key European markets.

  • Nycomed’s novel COPD therapy roflumilast receives FDA approval


    Nycomed's US partner Forest Laboratories, Inc. (NYSE: FRX) announced today that DalirespTM (roflumilast) was approved by the US Food and Drug Administration (FDA) as a treatment to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

  • Nycomed to acquire Colombian company Farmacol


    Nycomed today announced that it is expanding its presence in Latin America through the acquisition of Laboratorios Farmacol S.A., a Colombia based pharmaceutical company, which has a strong presence in the areas of gastroenterology, respiratory and gynaecology.

  • Nycomed Announces Agreement with Eurand for ZENPEP® in Russia-CIS


    ZURICH, Switzerland, and MILAN, Italy, January 12, 2011 – Nycomed, a privately owned global pharmaceutical company, and Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, announced today that Eurand has entered into an exclusive commercialization, license and supply agreement with Nycomed for Russia and the Commonwealth of Independent States (CIS), as well as Georgia and Mongolia.  Financial terms were not disclosed.

  • Daxas® (Roflumilast) included as a new treatment option in latest international COPD guidelines


    The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has included roflumilast (Daxas®) as a new treatment option in its COPD management guidelines. A section on the new class, phosphodiesterase 4 (PDE4) inhibitors, describes the efficacy of roflumilast in patients with COPD.


Takeda Pharma